Market capitalization | $670.00k |
Enterprise Value | $-3.82m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.31 |
EV/Sales (TTM) EV/Sales | -0.68 |
P/S ratio (TTM) P/S ratio | 0.12 |
P/B ratio (TTM) P/B ratio | 0.18 |
Revenue (TTM) Revenue | $5.64m |
EBIT (operating result TTM) EBIT | $-9.74m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Bellerophon Therapeutics, Inc.:
1 Analyst has issued a forecast Bellerophon Therapeutics, Inc.:
Sep '23 |
+/-
%
|
||
Revenue | 5.64 5.64 |
-
|
|
Gross Profit | 5.63 5.63 |
7,138%
7,138%
|
|
EBITDA | -9.73 -9.73 |
55%
55%
|
EBIT (Operating Income) EBIT | -9.74 -9.74 |
55%
55%
|
Net Profit | -9.25 -9.25 |
52%
52%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline include PH-ILD, PH-COPD, and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
Head office | United States |
CEO | Craig Jalbert |
Founded | 2009 |
Website | www.bellerophon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.